Bioheart Pursues OrCel Cardiac Regeneration; Ortec Chases Ulcer Claims
This article was originally published in The Gray Sheet
Executive Summary
Bioheart, Inc.'s Myocell may provide Ortec entry into the cardiovascular regeneration market, under a deal covering the cell transplantation product in combination with Ortec's OrCel collagen sponge and vascular endothelial growth factor technologies
You may also be interested in...
Ortec OrCel
Firm expects to complete filing of a PMA for the cryopreserved tissue product to treat venous leg ulcers by the end of January. The application is based on a 135-patient randomized trial comparing OrCel to standard compression therapy. Results of the trial, released Dec. 9, show that 12 weeks after application 59% of patients in the OrCel group achieved 100% closure compared to 36% of the control group - a 64% improvement. The average time to healing with OrCel was 57 days. Following completion of the PMA filing, Ortec plans to begin a pivotal trial to support a diabetic foot ulcer indication (1"The Gray Sheet" Aug. 5, 2002, p. 14)...
Ortec OrCel
Firm expects to complete filing of a PMA for the cryopreserved tissue product to treat venous leg ulcers by the end of January. The application is based on a 135-patient randomized trial comparing OrCel to standard compression therapy. Results of the trial, released Dec. 9, show that 12 weeks after application 59% of patients in the OrCel group achieved 100% closure compared to 36% of the control group - a 64% improvement. The average time to healing with OrCel was 57 days. Following completion of the PMA filing, Ortec plans to begin a pivotal trial to support a diabetic foot ulcer indication (1"The Gray Sheet" Aug. 5, 2002, p. 14)...
Medtronic Vascular Sales Remain Steady Despite Cypher Competition
Myocardial cell replacement is among therapies Medtronic's vascular unit is striving to develop to curb reliance on coronary stent sales